Cursor and Notification Center

The federal lab system is an enormous $50 billion-plus enterprise of internal research and development taking place in federal facilities across the United States. As other governments around the world, including China, pour billions of dollars into government labs and research parks focused on advanced technologies, it is imperative that we use all aspects of country’s own innovation ecosystem in the most creative ways possible, including our federal labs. 


Jodi Black

The National Institutes of Health funds what it calls extramural research in a wide variety of fields. Our guest has for many years worked to ensure that small enterprises got their share of the grants. Now she’s the recipient of a Tibbets Award from the Small Business Administration for advancing the Small Business Technology Transfer and Small Business Innovation Research programs. For more, the director of the Office of Clinical Policy and Programs at the FDA., Dr. Jodi Black, joined Federal Drive with Tom Temin.

Image: https://en.wikipedia.org/wiki/Jodi_Black#/media/File:Jodi_Black.jpg

NewImage

SARS-CoV-2 vaccinations are accelerating across the U.S. with approximately 66 million first doses having been administered as of February 25th, representing 13.6% of the country, according to NPR. The vaccination effort received another boost with the Food and Drug Administration’s recent Emergency Use Authorization (EUA) of Johnson & Johnson’s (J&J) single-dose vaccine. 

Image: https://biobuzz.io

GSK Logo

GSK Biologicals and its affiliate GSK Vaccines Institute for Global Health (GVGH) are currently working on two vaccine projects. The first is to prevent Group A Streptococcus infections, commonly known as Strep Throat, which is a major reason for antibiotic prescriptions and cause of immune-mediated diseases. 

The second project GSK is working is a vaccine to prevent infections caused by Salmonella enterica, which cause Invasive nontyphoidal salmonellosis (iNTS) disease and typhoid fever, major causes of death among children and significant health challenges primarily in sub-Saharan African countries. 

 

Notification Center

As the U.S. makes headway in its coronavirus vaccination campaign, Emergent BioSolutions CEO Bob Kramer appeared on CNBC Wednesday to explain his company’s role in manufacturing doses.

The Gaithersburg, Maryland-based contractor last year landed a multi-year deal to be the domestic producer of the Covid-19 vaccine from Johnson & Johnson, whose single-dose shot was cleared for use in the U.S. over the weekend. It also has a multi-year contract production contract for a vaccine developed by a British-Swedish biopharmaceutical company, AstraZeneca.

Image: https://www.cnbc.com/ - From Video

Qiagen Logo

HILDEN, Germany & GERMANTOWN, Md.--(BUSINESS WIRE)--QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) has launched its QIAsphere cloud-based platform that will allow labs and QIAstat-Dx users to monitor tests and instrument status remotely 24 hours a day, 7 days a week.

QIAsphere sets new standards for syndromic testing digital health, providing users with remote visibility of their testing routine. It can monitor a nearly unlimited number of instruments, providing visibility of testing routine across different hospitals or satellite labs. The continuous connectivity to QIAGEN service reduces systems downtime and enabling fast and accurate syndromic testing. Digital diagnostics and remote analytics will be crucial to bring syndromic testing closer to patients in the coming years.

CN Master RGB HiRes Lg

Washington, D.C.-based Children's National Hospital, Virginia Tech and Johnson & Johnson Innovation have partnered to launch a new healthcare technology and research innovation campus, according to a March 1 news release.

The Children's National Research & Innovation Campus will feature research into new pediatric medical treatments and technologies as well as a life sciences incubator for about 50 startups across the pharmaceutical, medical device, consumer and health tech sectors.

 

Marco and Debbie Chacón founded Paragon Bioservices.

(Photo courtesy of University of Maryland School of Law)

The entrepreneurs behind an exited Baltimore biotech company are creating a new center for immigration law in the city.

A $5 million gift from Marco and Debbie Chacón to the University of Maryland Francis King Carey School of Law will help to establish the Baltimore-based school’s new Chacón Center for Immigrant Justice.

The couple founded Paragon Bioservices, the contract manufacturing and development company that was acquired by Catalent in 2019 for $1.2 billion. Marco Chacón served as CEO and Debbie Chacón served as VP when the company moved to the University of Maryland BioPark in 2009. Now known as Paragon Gene Therapy, it still has a base at the BioPark, and Marco Chacón founded Irazú Bio, which is also based in the BioPark.

Image: Marco and Debbie Chacón founded Paragon Bioservices. (Photo courtesy of University of Maryland School of Law)

NewImage

All eyes are on the global rollout of COVID-19 vaccines. Achieving the broad uptake needed to reach population immunity and curb the virus’s spread will require an unprecedented effort among health workers, scientists and stakeholders at every step of the supply chain.

During this 90 min event, experts from organizations central to vaccine development and delivery, regulatory oversight and quality assurance will discuss over the course of two high-level panels what’s needed for the global COVID-19 vaccination campaign, how to build public trust in the quality and effectiveness of vaccines, and how these investments can build better systems for the future.

 

NewImage

Despite recent challenges, venture capital firms are still seeking out investment opportunities across the country. Since our last analysis of most active VCs in October 2020, we've seen shake-ups across 9 states. Our graphic maps out the most active VC investor in every US state.

Although startups based in California, New York, and Massachusetts have traditionally accounted for the majority of VC tech investment in the US, VCs are spurring other hotbeds of innovation across the country.

Image: https://www.cbinsights.com

BHI MCEDC LOGOS

Don’t miss a unique opportunity to discuss your biohealth technology innovation directly with Program Officers from NSF, various institutes at NIH, the University of Maryland MIPS program, and others.  Learn the latest about the current areas of focus for nondilutive funding resources, tips for submitting successful applications, and additional resources to support your early-stage company.  Confirmed speakers and partnering meeting participants include:

  • Henry Ahn - Program Director, National Science Foundation (NSF)
  • Lynne Stein Benzion – Director, Economic Development, Montgomery County Econ. Dev. Corp. (MCEDC)
  • Katie Bratlie - Program Director, National Science Foundation (NSF)
  • Christie Canaria, PhD - Program Director, SBIR Development Center, National Cancer Institute (NCI)
  • Judy Costello – Managing Director, Economic Development, BioHealth Innovation (BHI)
  • Stephanie Davis, PhD - Small Business Program Coordinator, NIH Nat’l Heart Lung & Blood Inst. (NHLBI)
  • Sharon Disque, Economic Development Manager, City of Gaithersburg, Maryland
  • Stephanie Fertig, HHS Small Business Program Lead, National Institutes of Health (NIH)
  • Jonathan Franca-Koh, PhD - Program Director, SBIR Development Center, National Cancer Inst (NCI).
  • Armineh Ghazarian - Program Analyst, NIH National Institute of Aging (NIA)
  • Colleen Gibney, SBIR Deputy Project Manager, USAMRMC (DoD)
  • Todd Haim, PhD - Chief, Office of Small Business Research, NIH National Institute of Aging (NIA)
  • Elena Koustova, PhD, MBA - Director, Office of Translational Initiatives and Program Innovations (OTIPI), NIDA SBIR/STTR Coordinator, NIH National Institute of Drug Abuse (NIDA) Office of Director
  • Ashwin Kulkarni, COO, miRecule; Associate, BioHealth Innovation, Inc. (BHI)
  • Carla Merritt, Senior Business Development Representative, Maryland Department of Commerce
  • JR Meyers, SBIR Project Manager, USAMRMC (DoD)
  • Alastair Monk - Program Director, National Science Foundation (NSF)
  • Deepa Narayanan - Program Director and Team Lead, NIH National Cancer Institute SBIR Development Center (NCI)
  • Rini Pek PhD - Senior Analyst, BioHealth Innovation, Inc. (BHI)
  • Erik Pierstorff - Program Director, National Science Foundation (NSF)
  • Victor Prikhodko - Senior Business Dev. Mgr., SBIR/STTR NIH National Inst. of Drug Abuse (NIDA)
  • Monique Pond, PhD - Program Director, SBIR Development Center, National Cancer Institute
  • Reema Railkar, PhD Program Manager, SBIR Development Center, National Cancer Institute
  • Saroj Regmi, PhD - Health Science Administrator, Office of Small Business Research, NIH National Institute of Aging
  • Andrea Renner - SBIR Deputy Project Manager, USAMRMC (DoD)
  • Ethel Rubin, PhD - Entrepreneur-in-Residence, BioHealth Innovation, Inc. (BHI)
  • Anthony Saleh, PhD – CEO, miRecule
  • Ben Schrag, PhD - Program Director, National Science Foundation (NSF)
  • John Sullivan - Entrepreneur-in-Residence, BioHealth Innovation, Inc. (BHI)
  • Onur Unal, Manager, Life Sciences Projects, Maryland Industrial Partnerships (MIPS), Maryland Technology Enterprise Institute (MTech), University of Maryland

Register (no fee) today!    www.tinyurl.com/2021SBIR

To see the full agenda, Click here.

BHI Logo

Are you a start-up in Maryland, DC or Virginia seeking feedback on your biohealth business idea, pitch deck, or commercialization plan? Schedule your feedback session with BHI EIRs here: www.tinyurl.com/EIRfeedback.  These take place by videoconference via Zoom.  Pre-registration and forwarding of a power point deck one week before the session is required. For questions, more information, or to be added to the wait list, please contact This email address is being protected from spambots. You need JavaScript enabled to view it..

Please review the available slots below and click on the button to register. Thank you!

 

Bendis Conference 2021

This free webinar will feature a fireside chat-style conversation with Dr. Robert Scharpf (Delfi Diagnostics) and Dr. Christie Bergerson (Exponent). Drs. Scharpf and Bergerson will discuss how machine learning and artificial intelligence are impacting biomedical engineering and the wider world of human health.

Rich Bendis (BioHealth Innovation/BioTalk podcast) will facilitate the discussion. View the speaker bios for more information.

After the main session, participants will have the opportunity to join one of three, smaller breakout sessions:

  • Meet and Greet with the Featured Speakers - Continue the conversation with Drs. Scharpf and Bergerson for an informal Q&A session about their work and the field.
  • Careers at the Intersection of Artificial Intelligence and Biotechnology - Join Rich Bendis and other industry representatives in exploring career opportunities in the emerging biotechnology, data science, and public health fields. 
  • What is Biocomputational Engineering? Learn about UMD's new bachelor's degree - Join program staff to learn about the exciting new University of Maryland degree aimed at preparing students for careers in the data science and biotechnology sector. Launching in Fall 2021 at the Universities at Shady Grove, this program is conveniently located in Rockville, MD – a biotech powerhouse just outside the nation's capital.

 

NewImage

 A free, virtual Forum focused on the growing Digital Health industry in the Baltimore/Washington region and beyond, presented by EAGB & BHI.

The Economic Alliance of Greater Baltimore (www.greaterbaltimore.org) and BioHealth Innovation (www.biohealthinnovation.org) have partnered to host a Forum focused on the growing Digital Health industry in the Baltimore/Washington region and beyond. The Forum is free and will be held virtually on March 25, from1 – 3:00 pm. There is no fee and all are welcomed, but you must register in order to receive the link to the event.

The Digital Health Forum features two panel discussions and a moderated conversation. Brief welcome comments by Rich Bendis and Michele Whelley, CEO of BHI and EAGB, respectively, will open the Forum.

  • PANEL ONE: The Role of Academia in Digital Health
  • PANEL TWO: Digital Health in Healthcare
  • CLOSING CONVERSATION: International Collaboration in Digital Health

Visit https://bit.ly/DigitalHealth21 to learn more and register for this FREE Event today.

Sponsored by: First National Bank, Olive, and TEDCO

 

PhlowUSP

Richmond, VA., February 22, 2021 – Phlow Corp., a public benefit essential medicines solutions provider, and the United States Pharmacopeia (USP) today announced a strategic alliance to develop a new laboratory that will certify and validate Pharmaceutical Continuous Manufacturing processes resulting in affordable, high-quality, U.S.-manufactured essential medicines. Throughout its 200-year history of setting standards for medicine quality, USP has been providing validated scientific methods used by manufacturers and regulators to determine what “good quality” looks like. The methods developed through this strategic alliance will be available for use by other domestic generics manufacturers to encourage broader adoption of Pharmaceutical Continuous Manufacturing in order to strengthen the U.S. drug supply.

USP, a global, scientific not-for-profit organization located in Rockville, Maryland, develops public standards that establish the quality expectations for medicines, collaborating with scientific experts from the academic, industry, and healthcare practitioner communities along with the U.S. FDA. The alliance will facilitate Phlow’s application of “flow” chemistry and other continuous advanced manufacturing processes to produce the crucial ingredients that enable domestic, end-to-end drug manufacturing of essential medicines that have been or are at risk of being in shortage thereby contributing to a more resilient medicines supply chain.

 

Emergent Logo

Emergent BioSolutions’ contract development and manufacturing (CDMO) business is playing a crucial role in supporting the battle against COVID-19. The company has contracted with multiple vaccine makers, including AstraZeneca and Johnson & Johnson, to manufacture the preventative medications.

It’s a critical role not taken lightly by the employees in the company’s two Baltimore-based facilities. Sean Kirk, executive vice president of Manufacturing and Technical Operations at Emergent, said the importance of the work taken on by Emergent, as well as the biopharma industry at large to battle the pandemic is not lost on him.

 

altimmune logo

Shares of Altimmune Inc. ALT were down 4.8% in trading on Thursday after the company said it started enrolling participants in a Phase 1 clinical trial for its COVID-19 vaccine candidate. Altimmune is developing a single-dose nasal spray vaccine. The study is expected to enroll up to 180 healthy adults between the ages of 18 and 55 years old, who will receive one of three doses of the experimental vaccine. The company said it expects to share the first batch of clinical data from this trial in the second quarter of this year. Altimmune's stock has soared 969.9% over the past 12 months, while the broader S&P 500 SPX is up 21.7%.

 

Qaigen Inovio

PLYMOUTH MEETING, Pa. and GERMANTOWN, Md. and HILDEN, Germany, Feb. 24, 2021 /PRNewswire/ -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) and INOVIO Pharmaceuticals (NASDAQ: INO) today announced an extension of their partnership with a new master collaboration agreement to develop liquid biopsy-based companion* diagnostic products based on next-generation sequencing (NGS) technology to complement INOVIO's therapies. (*Complementary when referring to the US regulatory pathway.)

 

Eric Feldman

ROCKVILLE, Md.--(BUSINESS WIRE)--Feb. 23, 2021-- GlycoMimetics, Inc. (Nasdaq: GLYC) today announced the promotion of Eric Feldman, M.D., to Senior Vice President and Chief Medical Officer. Dr. Feldman joined the Company in 2019 and was previously Vice President, Global Clinical Development.

“Eric is internationally recognized for his work in the development of new therapies for the treatment of leukemias and related bone marrow disorders, and in the past two years, has established himself as a leader in our management group as well as in the trenches with our clinical operations team. Having spent his career dedicated to patients with hematologic malignancies, he is especially well positioned to lead our uproleselan program as it advances through Phase 3 clinical trials. In addition, his extensive clinical research background will serve us well as we drive forward other programs in our pipeline,” said Rachel King, Chief Executive Officer.

 

NewImage

COLUMBIA, Md. (February 24, 2021)—TEDCO, Maryland’s economic engine for technology companies, announced today the appointment of Jack Miner as the chief investment officer. He begins his tenure with TEDCO on March 1, 2021.

“Jack brings many years of venture capital and leadership experience to fill this critical role at TEDCO,” said Troy LeMaile-Stovall, TEDCO’s CEO and executive director. “Leveraging his extensive knowledge of the entrepreneurial and venture capital community, we’re looking forward to the impact he will make in fostering TEDCO’s mission to better serve our entrepreneurs.” 

 

Tom Baden

Congratulations to the BHI Board-members who made the list.

  • Pete Briskman - Executive Managing Director Maryland , JLL
  • Ron Daniels - President, Johns Hopkins University
  • Dr. Jay Perman - Chancellor of the University System of Maryland
 

Biographer Robert Caro, in discussing his craft, wrote that “power reveals.” It reveals the true character of people, the nature of their endeavors, their goals and ambitions.

Welcome to The Daily Record’s inaugural Power 100 List.

We are recognizing the men and women across Maryland who are shaping our businesses, governments, nonprofits, law firms and other critical institutions. In essence, they are playing an outsize role in the culture, lifestyle, civic conversation and economic fortunes of Maryland.

 

NIHSBIR

Are you a BioHealth entrepreneur working with an academic institution on your oncology R&D?  The NCI SBIR Development Center has announced a new funding opportunity to support academic post-doc transitions to industry. This new and unique Fast-Track only award structure comprises a Phase I STTR that transitions to a Phase II SBIR. An STTR award is a collaborative award made to small businesses working closely with a university deadline to apply by 3/25.  For more information, check online:  Small Business Transition Grant | NCI: SBIR & STTR (cancer.gov)

Image: https://sbir.cancer.gov/funding/sbtg From Video

Concept rendering of George Mason University's Institute for Digital InnovAtion (IDIA) in Arlington

George Mason University President Gregory Washington on Monday announced he has formed an advisory roundtable of nearly 30 regional business executives and community leaders to focus on the university’s innovation initiative.

The President’s Innovation Advisory Council will focus on issues such as GMU’s efforts to increase the pipeline of tech workers. George Mason’s innovation initiative includes $235 million in General Assembly funding to produce approximately 30% of the 25,000 undergraduate and graduate majors as part of the state’s Tech Talent Investment Program.

Image: Concept rendering of George Mason University's Institute for Digital InnovAtion (IDIA) in Arlington

NewImage

SoPE + GW Startup Pitch Application Apply now to pitch at our March 24th Event: Pitch Perfect II: In Action!

Application is limited to SoPE members or those affiliated with George Washington University (students, staff, licensees, etc). Limited spots available. Submission does not guarantee acceptance.

Submission deadline: March 5th, 2021.

 

Daniel Sangjib Min - Times-Dispatch

Richmond-based pharmaceutical development company Phlow Corp. has formed a partnership with a nonprofit organization that will involve opening new laboratory operations in downtown Richmond.

Phlow, which is working to build the supply of medicines that face shortages in the U.S. market, said Monday that it has formed a strategic alliance with United States Pharmacopeia to develop a new laboratory operation in the Virginia Bio+Tech Research Park.

Image: Daniel Sangjib Min - Times-Dispatch

money

The National Institutes of Health (NIH) small business programs, which include the Small Business Innovation Research (SBIR) and the Small Business Technology Transfer (STTR) programs, are the largest source of early stage capital for life sciences startups in the United States.  The grant money helps startups accelerate their discoveries and put their discoveries into clinical trials.  The grants awarded are just that, a grant and not a loan; there is no requirement to pay back the money. The NIH grants $1.2 billion dollars every year in the combined SBIR and STTR programs.

 

BHI MCEDC LOGOS

Don’t miss a unique opportunity to discuss your biohealth technology innovation directly with Program Officers from NSF, various institutes at NIH (including NIA, NCI, NIDA, and NHLBI), the University of Maryland MIPS program.  Learn the latest about the current areas of focus for these funding resources, Tips and Tricks for submitting successful applications, and Additional Resources to support your early stage company.   Confirmed speakers and partnering meeting participants include:

  • Stephanie Davis, PhD - Small Business Program Coordinator, NIH National Heart Lung and Blood Institute (NHLBI)
  • Stephanie Fertig, HHS Small Business Program Lead, National Institutes of Health (NIH)
  • Armineh Ghazarian - Program Analyst, NIH National Institute of Aging
  • Colleen Gibney, SBIR Deputy Project Manager, USAMRDC
  • Henry Ahn - Program Director, National Science Foundation (NSF)
  • Todd Haim, PhD – Chief, Office of Small Business Research, NIH National Institute of Aging
  • Elena Koustova, PhD, MBA - Director, Office of Translational Initiatives and Program Innovations (OTIPI), NIDA SBIR/STTR Coordinator, NIH National Institute of Drug Abuse (NIDA) Office of Director
  • JR Meyers, SBIR Project Manager, USAMRDC
  • Victor Prikhodko – Senior Business Dev. Manager, SBIR/STTR NIH National Institute of Drug Abuse (NIDA)
  • Saroj Regmi, PhD - Health Science Administrator Office of Small Business Research, NIH National Institute of Aging
  • Andrea Renner - SBIR Deputy Project Manager, USAMRDC
  • Ben Schrag, PhD - Program Director, National Science Foundation (NSF)
  • Onur Unal, Manager, Life Sciences Projects, Maryland Industrial Partnerships (MIPS), Maryland Technology Enterprise Institute (Mtech), University of Maryland

 

Additional participants from the NIH National Cancer Institute and other resources TBA.

Click here to.. Reserve your spot (no fee) today!